Plexxikon initiates Phase 1 trial for PLX5568
Plexxikon Inc. Kathleen Sereda Glaub, 510-647-4009 President kglaub@plexxikon.com or For Plexxikon Inc. Jennifer Cook Williams, 360-668-3701 jennifer@cwcomm.org Plexxikon Inc. today announced that it has initiated a Phase 1 human clinical trial for PLX5568, a novel kinase inhibitor targeted for the treatment of at least two major indications with unmet medical needs: pain as well as
PLX Technology today announced it will host a conference call and Webcast to discuss its fourth quarter and fiscal year 2008 financial results, along with the Company's business outlook, on Monday, Jan. 26, 2009, at 2:00 pm, following the release of the Company's financial results.